Clinical Trial Update: A Prospective, One-arm and Open Clinical Study of Zanubrutinib in the Treatment of Immune Thrombocytopenia [Phase 2]

View source ↗

Summary

A Phase 2, single-arm, open-label trial to evaluate zanubrutinib for immune thrombocytopenia is recruiting in China. The study is sponsored by the Institute of …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immune Thrombocytopenia

Drugs mentioned

• BRUKINSA (ZANUBRUTINIB)

Snippet

Sponsor: Institute of Hematology & Blood Diseases Hospital, China | Conditions: Immune Thrombocytopenia, Treatment | Phase 2 | Status: RECRUITING